Holista LLC dba HolistaPet

Warning LetterOpen

Dareh Zadoorian Chief Executive Officer/Registered Agent Holista LLC dba HolistaPet United States support@holistapet.com support@holistapet.coIssued Apr 7, 2025Center for Veterinary Medicine

View Letter

Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy.

Violations3

Issue DateApr 7, 2025

Product TypeAnimal & Veterinary

StatusOpen

Letter Details

Firm: Holista LLC dba HolistaPet
Location: Dareh Zadoorian Chief Executive Officer/Registered Agent Holista LLC dba HolistaPet United States support@holistapet.com support@holistapet.co
FEI Number: N/A
Country: United States
Issue Date: April 07, 2025
Issuing Office: Center for Veterinary Medicine
Product Type: Animal & Veterinary
Status: Open

Summary

Holista LLC dba HolistaPet was cited for marketing unapproved new animal drugs, specifically multiple CBD-containing products for dogs, cats, and horses (including CBD oils, treats, chews, pellets, and capsules) without FDA approval. The FDA determined these products violated the Federal Food, Drug, and Cosmetic Act by being unsafe under Section 512(a) and adulterated under Section 501(a)(5), as the company made therapeutic claims on its website www.holistapet.com and social media platforms (Instagram and Pinterest) that established the products as drugs intended for animal use. The company was prohibited from introducing or delivering these unapproved products into interstate commerce under Section 301(a) of the FD&C Act.

Holista LLC dba HolistaPet FDA Warning Letter, April 7, 2025